Fukang (Shanghai) Health Technology
Researcher and developer of innovative drugs focused on oncology treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY100m | Series C | |
| Total Funding | 000k | ||
Related Content
Convalife (Shanghai) Health Technology Co., Ltd., operating as Convalife Pharmaceuticals, is a clinical-stage biopharmaceutical company established in 2015 with a focus on developing treatments for oncology, virology, and age-related diseases. The company was founded by Dr. Xiaokun Shen, who also serves as the chairman and CEO. Convalife operates with a global perspective, maintaining its headquarters in Shanghai and additional offices in Guangzhou and Boston.
The company's business model centers on the research and development of original drugs with "First-in-Class" or "Best-in-Class" potential to address unmet medical needs worldwide. Convalife has a robust pipeline that includes small molecule drugs and bispecific antibodies. Key products in development include CVL218, a second-generation PARP inhibitor, and CVL237, a highly selective PI3K β/δ dual inhibitor. The company's portfolio targets a range of cancers such as breast, lung, prostate, and pancreatic cancer, as well as various infectious diseases like COVID-19 and Respiratory Syncytial Virus (RSV). Revenue generation is driven by strategic partnerships, licensing agreements, and venture capital funding. The company has successfully raised significant capital through multiple funding rounds, including a Series C in January 2024 for $14 million.
Convalife has established numerous strategic collaborations to advance its pipeline. In August 2024, it partnered with Shanghai Henlius Biotech, granting them exclusive rights to commercialize neratinib (HANNAIJIA) in China for HER2-positive breast cancer treatment. This drug was approved by China's NMPA in June 2024. Another significant agreement was made in July 2022, when Convalife acquired the global rights for the PI3K β/δ inhibitor CVL-237 from Karus Therapeutics Ltd. The company also collaborates with other major entities like Hutchmed (China) Ltd. and Wuxi Biologics for combination therapies and development support, respectively.
Keywords: Convalife Pharmaceuticals, clinical-stage biopharmaceutical, innovative drug development, oncology, virology, age-related diseases, Dr. Xiaokun Shen, small molecule drugs, bispecific antibodies, PARP inhibitor, CVL218, PI3K inhibitor, CVL237, neratinib, strategic partnerships, venture capital, cancer treatment, infectious disease, Shanghai, Guangzhou, Boston